Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-01-26
- Last Posted Date
- 2007-11-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 77
- Registration Number
- NCT00102219
- Locations
- 🇻🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Caracas, Venezuela
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
- Conditions
- Carcinoma, Transitional Cell
- First Posted Date
- 2005-01-17
- Last Posted Date
- 2006-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 61
- Registration Number
- NCT00101842
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas, United States
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT00100776
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Raleigh, North Carolina, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tacoma, Washington, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5-hours, EST), or speak with your personal physician, Clementon, New Jersey, United States
Comparing Intensive and Standard Training for Human Insulin Inhalation Powder (HIIP)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY041001 (HIIP)
- First Posted Date
- 2004-12-16
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 97
- Registration Number
- NCT00099515
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., George, South Africa
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
- Conditions
- Coronary ArteriosclerosisAcute Coronary Syndromes
- Interventions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13619
- Registration Number
- NCT00097591
- Locations
- 🇺🇸
For more information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), Global Quintiles Study Line (1-866-615-4672) or speak with your physician, Indianapolis, Indiana, United States
Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00097383
- Locations
- 🇵🇹
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Santarem, Portugal
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-11-19
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT00097227
- Locations
- 🇺🇸
ImClone Investigational Site, Morgantown, West Virginia, United States
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: Cetuximab
- First Posted Date
- 2004-11-19
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 57
- Registration Number
- NCT00097214
- Locations
- 🇺🇸
ImClone Investigational Site, Philadelphia, Pennsylvania, United States
Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 939
- Registration Number
- NCT00095199
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St-Jerome, Quebec, Canada
Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2004-10-22
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00094640
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Barcelona, Spain